Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCProject_3216_T1_RNA

— · A

c428eb33-1a62-5209-9819-a1038e8100a2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • HEDGEHOG_SIGNALING+0.500
  • TGF_BETA_SIGNALING+0.500
  • TNFA_SIGNALING_VIA_NFKB+0.480
  • ANGIOGENESIS+0.430
  • UV_RESPONSE_DN+0.400
  • MYOGENESIS+0.390
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
  • ADIPOGENESIS+0.370
  • HYPOXIA+0.360
  • APICAL_JUNCTION+0.300

Top 10 suppressed

  • E2F_TARGETS-0.400
  • DNA_REPAIR-0.380
  • MYC_TARGETS_V1-0.340
  • MYC_TARGETS_V2-0.320
  • G2M_CHECKPOINT-0.290
  • UNFOLDED_PROTEIN_RESPONSE-0.170
  • OXIDATIVE_PHOSPHORYLATION-0.160
  • ESTROGEN_RESPONSE_LATE-0.130
  • SPERMATOGENESIS-0.120
  • INTERFERON_ALPHA_RESPONSE-0.100

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR23303755
bladder-landscape@3
——0.880
2TCGA-BH-A1FE-06A-11R-A213-07
breast-umap@18
—A0.878
3TCGA-BH-A0DV-01A-21R-A12P-07
breast-umap@18
—A0.875
4MBCProject_0419_T2_RNA
breast-umap@18
—A0.875
5MBCProject_0381_T2_RNA
breast-umap@18
—A0.862
6SRR8613813
breast-umap@18
—D0.855
7SRR12696728
melanoma-umap@29
——0.853
8TCGA-AO-A0JF-01A-11R-A056-07
breast-umap@18
—A0.851
9MBCProject_0734_T1A_RNA
breast-umap@18
—A0.848
10TCGA-AC-A2B8-01A-11R-A17B-07
breast-umap@18
—A0.846

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 34 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
HEDGEHOG_SIGNALING0.500Inavolisib— uncovered
TGF_BETA_SIGNALING0.500Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.480Inavolisib— uncovered
ANGIOGENESIS0.430Remibrutinib— uncovered
UV_RESPONSE_DN0.400Inavolisib— uncovered
MYOGENESIS0.390Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.380Inavolisib— uncovered
ADIPOGENESIS0.370Inavolisib— uncovered
HYPOXIA0.360Idelalisib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
KRAS_SIGNALING_UP0.270Inavolisib— uncovered
APOPTOSIS0.260Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.260Inavolisib— uncovered
HEME_METABOLISM0.240Temsirolimus— uncovered
NOTCH_SIGNALING0.240Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.240Inavolisib— uncovered
COMPLEMENT0.230Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.230Inavolisib— uncovered
FATTY_ACID_METABOLISM0.220Inavolisib— uncovered
IL2_STAT5_SIGNALING0.210Idelalisib— uncovered